

Experience of MTZ Clinical Research in Late Clinical Development

Biosimilarity – Phase III

| Lp. | Therapeutic /Chemical subgroup | Chemical substance | Indication / Population |
|-----|---------------------------------------|--------------------|----------------------------|
| 138 | Monoclonal antibodies | Adalimumab | Plaque Psoriasis |
| 139 | Monoclonal antibodies | Adalimumab | Plaque Psoriasis |
| 140 | Monoclonal antibodies | Adalimumab | Plaque Psoriasis |
| 141 | Monoclonal antibodies | Adalimumab | Plaque Psoriasis |
| 142 | Monoclonal antibodies | Adalimumab | Rheumatoid arthritis |
| 143 | Monoclonal antibodies | Bevacizumab | Non-small cell Lung Cancer |
| 144 | TNF- α inhibitors | Etanercept | Plaque Psoriasis |
| 145 | TNF- α inhibitors | Etanercept | Rheumatoid arthritis |
| 146 | Monoclonal antibodies | Infliximab | Rheumatoid arthritis |
| 147 | Peptide hormone | Insulin glargine | Type 2 diabetes mellitus |
| 148 | Granulocyte colony-stimulating factor | Pegfilgrastim | Neutropenia |
| 149 | Granulocyte colony-stimulating factor | Pegfilgrastin | Neutropenia |
| 150 | Monoclonal antibodies | Rituximab | Rheumatoid arthritis |

Phase III Studies

| Lp. | Therapeutic/Chemical subgroup | Indication / Population |
|---|------------------------------------|---------------------------------------|
| Alimentary tract and metabolism | | |
| 151 | Drugs used in diabetes | Type 2 diabetes mellitus |
| Antineoplastic and immunomodulating agents | | |
| 152 | Immunoglobulin | (AL) Amyloidosis |
| 153 | Monoclonal antibodies | (ALL) Acute Lymphoblastic Leukemia |
| 154 | Selective immunosuppressants | (ALL) Acute Lymphoblastic Leukemia |
| 155 | FLT3 Inhibitor | (ALL) Acute Lymphoblastic Leukemia |
| 156 | FLT3 Inhibitor | (ALL) Acute Lymphoblastic Leukemia |
| 157 | Tyrosine kinase inhibitor (TKI) | (CML) Chronic Myelogenous Leukemia |
| 158 | Tyrosine kinase inhibitor (TKI) | (CML) Chronic Myelogenous Leukemia |
| 159 | Tyrosine kinase inhibitor (TKI) | (CML) Chronic Myelogenous Leukemia |
| 160 | Bruton's tyrosine kinase inhibitor | (CLL) Chronic Lymphocytic Leukemia |
| 161 | Bruton's tyrosine kinase inhibitor | (CLL) Chronic Lymphocytic Leukemia |
| 162 | Inhibitor of kinase (PI3K) | (CLL) Chronic Lymphocytic Leukemia |
| 163 | Inhibitor of kinase (PI3K) | (CLL) Chronic Lymphocytic Leukemia |
| 164 | Monoclonal antibodies | (DLBCL) Diffuse Large B-Cell Lymphoma |
| 165 | Histone deacetylase inhibitor | (DLBCL) Diffuse Large B-Cell Lymphoma |

MTZ Clinical Research Sp. z o.o.

Pawinkiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



Experience of MTZ Clinical Research

Late Clinical Development

| Lp. | Therapeutic/Chemical subgroup | Indication / Population |
|-----|---|---|
| 166 | Protein kinase inhibitors | (DLBCL) Diffuse Large B-Cell Lymphoma |
| 167 | Monoclonal antibodies | Gastric cancer |
| 168 | Janus kinase (JAK) inhibitor | Graft Versus Host Disease |
| 169 | Monoclonal antibodies | Hepatocellular carcinoma |
| 170 | Monoclonal antibodies | Hepatocellular carcinoma |
| 171 | Protein kinase inhibitors | Hepatocellular carcinoma |
| 172 | Monoclonal antibodies | Hodgkin Lymphoma |
| 173 | Bruton's tyrosine kinase inhibitor | Mantle Cell Lymphoma |
| 174 | Monoclonal antibodies | Multiple Myeloma |
| 175 | Proteasome inhibitor | Multiple Myeloma |
| 176 | Proteasome inhibitor | Multiple Myeloma |
| 177 | Proteasome inhibitor | Multiple Myeloma |
| 178 | Monoclonal antibodies | Multiple Myeloma |
| 179 | Monoclonal antibodies | Multiple Myeloma |
| 180 | Inhibitor of kinase (PI3K) | (MDS) Myelodysplastic syndrome |
| 181 | Antimetabolites | (MDS) Myelodysplastic syndrome |
| 182 | Antianemic preparations | (MDS) Myelodysplastic syndrome |
| 183 | Protein kinase inhibitors | Myelofibrosis |
| 184 | Monoclonal antibodies | (PNH) Paroxysmal nocturnal hemoglobinuria |
| 185 | Mistletoe Extract | Pancreatic Cancer |
| | Antiinfectives for systemic use | |
| 186 | Immune sera and immunoglobulins | (ITP) Idiopathic thrombocytopenic purpura |
| 187 | Antivirals for systemic use | CMV positive patients |
| | Blood and blood forming organs | |
| 188 | Antianemic preparations | Chemotherapy Induced Anemia |
| | Cardiovascular system | |
| 189 | Cardiac therapy | Orthostatic Hypotension |
| 190 | Vasoprotectives | Telangiectasia and lipodystrophy |
| | Dermatologicals | |
| 191 | Corticosteroids | Acne vulgaris |
| 192 | Corticosteroids | Acne vulgaris |
| 193 | Monoclonal antibodies | Atopic Dermatitis |
| 194 | Janus kinase (JAK) inhibitor | Atopic Dermatitis |
| 195 | Janus kinase (JAK) inhibitor | Atopic Dermatitis |
| 196 | Janus kinase (JAK) inhibitor | Atopic Dermatitis |
| 197 | Janus kinase (JAK) inhibitor | Atopic Dermatitis |
| 198 | Phosphodiesterase type 4 inhibitor (PDE4) | Atopic Dermatitis |
| 199 | Interleukin inhibitors | Plaque Psoriasis |
| 200 | Interleukin inhibitors | Plaque Psoriasis |
| 201 | Janus kinase (JAK) inhibitor | Plaque Psoriasis |
| 202 | Janus kinase (JAK) inhibitor | Plaque Psoriasis |
| 203 | Interleukin inhibitors | Plaque Psoriasis |
| 204 | TNF- α inhibitors | Psoriatic arthritis |

Date of issue: May 2019

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN



Experience of MTZ Clinical Research

Late Clinical Development

| Lp. | Therapeutic/Chemical subgroup | Indication / Population |
|-----|---|--|
| | Genito-urinary system and sex hormones | |
| 205 | Gonadatropin releasing hormone | Endometriosis-associated pain |
| 206 | Gonadatropin releasing hormone | Endometriosis-associated pain |
| | Musculo-skeletal system | |
| 207 | Monoclonal antibodies | Osteoarthritis of the hip or knee |
| 208 | Monoclonal antibodies | After a Total Knee, Hip, or Shoulder Replacement |
| 209 | Janus kinase (JAK) inhibitor | Rheumatoid arthritis |
| 210 | Janus kinase (JAK) inhibitor | Rheumatoid arthritis |
| | Nervous system | |
| 211 | Inhibitor of Tau protein aggregation | Alzheimer's Disease |
| 212 | Inhibitor of Tau protein aggregation | Alzheimer's Disease |
| | Respiratory system | |
| 213 | Drugs for obstructive airway diseases | Asthma |
| 214 | Drugs for obstructive airway diseases | (COPD) Chronic obstructive pulmonary disease |
| 215 | Growth hormone (GH) stimulation test | Growth hormone deficiency |

Date of issue: May 2019

MTZ Clinical Research Sp. z o.o.

Pawinskiego 5, 02-106 Warsaw, Poland

+48 22 572 59 59 +48 22 572 59 57

info@mtz-clinical.pl

mtz-clinical.pl

VAT N° PL 526 26 35 334

BUSINESS REGISTER N° 015209197

NATIONAL COURT REGISTER N° 0000129520

INITIAL CAPITAL: 208 500 PLN

